DK2361609T3 - Formulering af småmolekylære lægemidler med forsinket frigivelse - Google Patents

Formulering af småmolekylære lægemidler med forsinket frigivelse

Info

Publication number
DK2361609T3
DK2361609T3 DK11162857.4T DK11162857T DK2361609T3 DK 2361609 T3 DK2361609 T3 DK 2361609T3 DK 11162857 T DK11162857 T DK 11162857T DK 2361609 T3 DK2361609 T3 DK 2361609T3
Authority
DK
Denmark
Prior art keywords
delayed
formulation
molecule drugs
release small
release
Prior art date
Application number
DK11162857.4T
Other languages
English (en)
Inventor
Andrew S Luk
Gunjan Junnarkar
Guohua Chen
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37906769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2361609(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Durect Corp filed Critical Durect Corp
Application granted granted Critical
Publication of DK2361609T3 publication Critical patent/DK2361609T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK11162857.4T 2005-09-30 2006-09-28 Formulering af småmolekylære lægemidler med forsinket frigivelse DK2361609T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72284505P 2005-09-30 2005-09-30
EP06825283A EP1940351B1 (en) 2005-09-30 2006-09-28 Sustained release small molecule drug formulation

Publications (1)

Publication Number Publication Date
DK2361609T3 true DK2361609T3 (da) 2013-08-26

Family

ID=37906769

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06825283.2T DK1940351T3 (da) 2005-09-30 2006-09-28 Formulering af småmolekylære lægemidler med langvarig frigørelse
DK11162857.4T DK2361609T3 (da) 2005-09-30 2006-09-28 Formulering af småmolekylære lægemidler med forsinket frigivelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK06825283.2T DK1940351T3 (da) 2005-09-30 2006-09-28 Formulering af småmolekylære lægemidler med langvarig frigørelse

Country Status (14)

Country Link
US (6) US8852638B2 (da)
EP (2) EP1940351B1 (da)
JP (3) JP2009510116A (da)
CN (1) CN101365423B (da)
AR (1) AR056554A1 (da)
AT (1) ATE551989T1 (da)
AU (1) AU2006299657B2 (da)
CA (1) CA2624088C (da)
DK (2) DK1940351T3 (da)
ES (2) ES2422681T3 (da)
IL (1) IL190499A (da)
PL (1) PL2361609T3 (da)
TW (1) TW200803920A (da)
WO (1) WO2007041410A2 (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
JP2005519873A (ja) * 2001-11-14 2005-07-07 アルザ・コーポレーション カテーテル注入可能なデポー組成物およびそれらの使用
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CN103637977A (zh) * 2005-07-18 2014-03-19 宾夕法尼亚大学理事会 含药植入物及其使用方法
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CA2686137C (en) * 2007-05-18 2021-01-12 Durect Corporation Improved depot formulations
EP2152315B1 (en) * 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
EP2529757B1 (en) * 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
ES2589106T3 (es) 2010-05-31 2016-11-10 Laboratorios Farmaceuticos Rovi, S.A. Composición inyectable antipsicótica de liberación controlada
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
HRP20211853T1 (hr) 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Sastavi in situ injekcijskih biorazgradivih implantata
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
DE102013011399A1 (de) 2012-07-31 2014-02-06 Amw Gmbh Implantat mit Risperidon
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
BR112015022023B1 (pt) 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
AU2015253417B2 (en) 2014-04-28 2020-02-20 Dimerx, Inc. Pharmaceutically active dimers linked through phenolic hydroxyl groups
CN104288091B (zh) * 2014-05-30 2017-04-19 河南科技大学 一种利培酮纳米混悬温敏凝胶剂及其制备方法
WO2016071767A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
CN104398474A (zh) * 2014-11-21 2015-03-11 内蒙古医科大学附属医院 一种利培酮鼻用凝胶剂及其制备方法
ES2960753T3 (es) 2015-09-21 2024-03-06 Teva Pharmaceuticals Int Gmbh Formulaciones de olanzapina de liberación sostenida
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
CN105542480B (zh) * 2016-03-07 2018-04-17 山东理工大学 一种用聚己内酯与p(cpp‑sa)‑聚乙二醇改进聚乙烯醇膜耐水性及柔顺性的方法
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
BR112018077259A2 (pt) 2016-06-30 2019-06-18 Durect Corporation formulações depot
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
US11752099B2 (en) * 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
WO2019125358A1 (en) * 2017-12-18 2019-06-27 Foresee Pharmaceuticals Pharmaceutical compositions having a selected release duration
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
EP3914254A4 (en) * 2019-01-22 2022-11-23 Indivior UK Limited Methods for treating schizophrenia
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症
US10813882B1 (en) * 2019-11-25 2020-10-27 King Abdulaziz University In situ gelling formulation for reduced initial drug burst
WO2021237039A1 (en) * 2020-05-21 2021-11-25 Veru Inc. Compositions and methods for long term release of gonadotropin-releasing hormone (gnrh) antagonists
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form
US12472148B2 (en) 2021-04-26 2025-11-18 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
CN118284414A (zh) 2021-07-06 2024-07-02 M·哈斯莱顿 血清素再摄取抑制剂戒断综合征的治疗
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
EP4527389A1 (en) 2022-05-18 2025-03-26 Laboratorios Farmacéuticos Rovi S.A. Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB806876A (en) 1956-02-16 1959-01-07 Wellcome Found Improvements in and relating to disposable hypodermic injection devices
GB873526A (en) 1957-08-14 1961-07-26 Upjohn Co Fluid compositions comprising (acetyl-salicylic acid)-anhydride
GB887872A (en) 1958-06-25 1962-01-24 Upjohn Co Improvements in or relating to pharmaceutical preparations
DE1467938C3 (de) 1964-05-22 1973-12-20 F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) Wasserdispergierbares Arzneipräparat für Tiere
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4891225A (en) 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4534974A (en) 1984-07-31 1985-08-13 Carter-Wallace, Inc. Pharmaceutical compositions with codeine
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
GB8522453D0 (en) 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
JPS62298530A (ja) 1986-06-16 1987-12-25 Otsuka Pharmaceut Co Ltd 坐薬用医薬組成物
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
CA2002299A1 (en) 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
DE3927113C2 (de) 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
US5096715A (en) 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
US5660851A (en) 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
EP0532546B1 (en) 1990-05-10 1998-03-18 Bechgaard International Research And Development A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
JPH0456736A (ja) 1990-06-22 1992-02-24 Ngk Insulators Ltd 金属溶湯用フィルターカートリッジ
JPH0456736U (da) 1990-09-14 1992-05-15
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
AU668679B2 (en) 1991-02-18 1996-05-16 Transdermal Technologies Pty Limited Composition for use in transdermal administration
JP2907624B2 (ja) 1991-02-28 1999-06-21 株式会社日本触媒 新規含フッ素フタロシアニン化合物、その製造方法、およびそれらを含んでなる近赤外線吸収材料
JP3145742B2 (ja) 1991-09-19 2001-03-12 日東電工株式会社 ゴム系感圧性接着剤とその接着シ―ト
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
PT669128E (pt) 1992-11-17 2000-06-30 Yoshitomi Pharmaceutical Micro-esfera de libertacao sustentada contendo antipsicoticos e processo para produzir a mesma
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
NZ260909A (en) 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
EP2275089A1 (en) 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Preparation of biodegradable microparticles containing a biologically active agent
ES2236700T3 (es) 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
CA2187353C (en) 1994-04-08 2007-05-22 Gerald L. Yewey Liquid delivery compositions
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
WO1996021427A1 (en) 1995-01-09 1996-07-18 Atrix Laboratories, Inc. Liquid polymer delivery system
JP3274579B2 (ja) 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
JP4330175B2 (ja) 1995-06-07 2009-09-16 デュレクト コーポレイション 高粘度液体による制御された送達系
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TR199802258T2 (en) 1996-05-07 2001-11-21 Janssen Pharmaceutica N.V. Mikropar�ac�klar.
JP4346696B2 (ja) 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
IL127603A (en) 1996-06-17 2001-08-08 Janssen Pharmaceutica Nv A process for preparing rapidly dissolving solid dosage forms and the dosage forms obtained in this process
US6130200A (en) * 1996-12-20 2000-10-10 Alza Corporation Gel composition and methods
DE19701912C1 (de) 1997-01-10 1998-05-14 Jenapharm Gmbh Injizierbares Implantat
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
AU3273497A (en) 1997-06-23 1999-01-04 Marco Cecchini Inhaling device
IT1292396B1 (it) 1997-06-23 1999-02-08 Lisapharma Spa Cerotto dermico avente elevata resistenza meccanica,flessibilita' trasparenza e conducibilita' elettrica nel trattamento di affezioni
US6622036B1 (en) 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
DE69916911T2 (de) 1998-02-10 2005-04-21 Gen Electric Brenner mit gleichmässiger Brennstoff/Luft Vormischung zur emissionsarmen Verbrennung
ES2359973T3 (es) 1998-03-19 2011-05-30 MERCK SHARP & DOHME CORP. Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas.
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
DE19923551A1 (de) 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
AU2001237221A1 (en) 2000-01-11 2001-07-24 Roland Bodmeier Implants, particles
KR100393478B1 (ko) 2000-03-29 2003-08-06 주식회사종근당 자가유화 매트릭스형 경점막·경피흡수제제
US6897308B1 (en) 2000-05-05 2005-05-24 Rgp Life Sciences Limited Process for the preparation of anti-psychotic 3-[2-[-4-(6-fluoro-1,2-benziosoxazol-3-yl)-1-piperidinyl] ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
NZ523385A (en) * 2000-06-28 2005-09-30 Atul J Biodegradable vehicles and BAS-loaded delivery systems for use as biodegradable fillers and/or spacers, e.g. artificial skin
DE10035889A1 (de) 2000-07-24 2002-02-14 Lohmann Therapie Syst Lts Medizinischer Haftkleber mit einem Gehalt an Zucker-Estern
ATE401313T1 (de) 2000-08-14 2008-08-15 Teva Pharma Herstellung von risperidon
DE10044545A1 (de) 2000-09-05 2002-04-04 Roland Bodmeier Retardpartikeldispersion
IT250575Y1 (it) 2000-10-10 2003-09-24 Gimatic Spa Sistema di guida registrabile per griffe di pinze azionate da unfluido
AU2002226000A1 (en) 2000-11-13 2002-05-21 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
EP1335704A2 (en) 2000-11-16 2003-08-20 Durect Corporation Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
CA2439120C (en) 2001-02-23 2011-07-05 Genentech, Inc. Erodible polymers for injection
US20040018238A1 (en) * 2001-02-26 2004-01-29 Shukla Atul J Biodegradable vehicles and delivery systems of biolgically active substances
WO2002076344A1 (en) 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
GB0112324D0 (en) 2001-05-21 2001-07-11 Croda Int Plc Compounds
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
JP2003063954A (ja) 2001-08-24 2003-03-05 Saitama Daiichi Seiyaku Kk リザーバー型貼付剤
CA2466632C (en) 2001-11-14 2014-02-11 Alza Corporation Injectable depot compositions and uses thereof
WO2003041685A1 (en) 2001-11-14 2003-05-22 Alza Corporation Injectable depot composition
JP2005519873A (ja) 2001-11-14 2005-07-07 アルザ・コーポレーション カテーテル注入可能なデポー組成物およびそれらの使用
US20040258731A1 (en) 2001-11-21 2004-12-23 Tsuyoshi Shimoboji Preparation approriate for cartilage tissue formation
AU2003227827B2 (en) 2002-03-12 2008-09-25 Ethypharm Composition having gelling properties for the prolonged delivery of bioactive substances
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
TWI314464B (en) 2002-06-24 2009-09-11 Alza Corp Reusable, spring driven autoinjector
TWI353854B (en) 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
EP2030611A1 (en) 2002-07-31 2009-03-04 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
AU2003257994A1 (en) 2002-07-31 2004-02-16 Alza Corporation Injection device providing automatic needle retraction
WO2004020439A2 (en) 2002-08-30 2004-03-11 Sunil Sadanand Nadkarni Improved process for preparation of risperidone
EP1556091A1 (en) 2002-10-04 2005-07-27 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20120225033A1 (en) 2010-11-24 2012-09-06 Durect Corporation Biodegradable Drug Delivery Composition
KR20040034996A (ko) 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
CA2503076A1 (en) 2002-10-25 2004-05-06 Pfizer Products Inc. Novel injectable depot formulations
WO2004043432A2 (en) 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
EP2959893A1 (en) 2002-12-13 2015-12-30 DURECT Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
AU2003297087B2 (en) 2003-02-04 2009-06-11 Philip Morris Products S.A. Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
ES2570454T3 (es) 2003-03-26 2016-05-18 Egalet Ltd Sistema de liberación controlada de morfina
WO2004094414A1 (en) 2003-04-22 2004-11-04 Synthon B.V. Water soluble salts of risperidone
CN1822816A (zh) 2003-05-30 2006-08-23 阿尔萨公司 可植入的弹性体储库组合物、其用途以及制备方法
DK1635875T3 (da) 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
FI20045223L (fi) 2004-06-15 2005-12-16 Bioretec Oy Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin
US20050032781A1 (en) 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070108405A1 (en) 2003-09-01 2007-05-17 Fh Faulding & Co., Ltd. Compositions and methods for delivery of biologically active agents
WO2005037949A2 (en) 2003-10-07 2005-04-28 Chrysalis Technologies Incorporated Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
WO2005056077A2 (en) 2003-12-05 2005-06-23 Aradigm Corporation A device for readying a needle free injector for delivery
AU2004313245B2 (en) 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
EP2633853A1 (en) 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Long-term delivery formulations and methods of use thereof
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
EP1729676A1 (en) 2004-03-15 2006-12-13 Durect Corporation Pharmaceutical compositions for administration to a sinus
IS7290A (is) 2004-05-28 2005-11-29 Actavis Group Lyfjasamsetningar sem innihalda risperidone
MXPA06014095A (es) 2004-06-04 2007-08-07 Camurus Ab Formulaciones de deposito de lipidos.
EP1604693A1 (en) 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
MX2007003789A (es) 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
ES2385386T3 (es) 2004-10-21 2012-07-24 Durect Corporation Sistemas de administración transdérmica
RS53890B1 (sr) 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. Stabilizovan polimerni sistem za isporuku
GB2420976B (en) 2004-11-19 2006-12-20 Zvi Finkelstein Therapeutic implant
AR052155A1 (es) 2004-12-14 2007-03-07 Novartis Ag Compuestos organicos
JP2008524235A (ja) 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． オクトレオチド化合物の徐放性送達処方物
CA2527666C (en) 2004-12-16 2008-09-23 Miv Therapeutics Inc. Multi-layer drug delivery device and method of manufacturing same
US9415034B2 (en) 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
WO2006133506A1 (en) 2005-06-17 2006-12-21 Vital Health Sciences Pty Ltd A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
CN103637977A (zh) 2005-07-18 2014-03-19 宾夕法尼亚大学理事会 含药植入物及其使用方法
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2007017712A1 (en) 2005-08-11 2007-02-15 Promedon Do Brasil Produtos Medico-Hospitalares Ltda. Composition comprising polymeric, water-insoluble, anionic particles, processes and uses
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007050975A2 (en) 2005-10-26 2007-05-03 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
RU2427383C2 (ru) 2006-01-18 2011-08-27 КьюПиЭс, ЭлЭлСи Фармацевтические композиции с повышенной стабильностью
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
EP2248519B1 (en) 2006-10-02 2017-12-06 Apr Applied Pharma Research S.A. Non-mucoadhesive film dosage forms
CL2007002851A1 (es) 2006-10-05 2008-01-18 M S Panacea Biotec Ltd Composicion inyectable que comprende micro o nano -particulas biodegradables que incluyen un agente activo, un polimero biodegardable, un agente para intensificar la viscosidad y excipiente farmaceuticamente aceptables; y procedimientos de preparacion
PL2079767T3 (pl) 2006-10-11 2015-05-29 Tolmar Therapeutics Inc Wytwarzanie biodegradowalnych poliestrów z właściwościami niskiego wyrzutu przez ekstrakcję płynem nadkrytycznym
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
GB0620661D0 (en) 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
DK2115029T3 (da) 2007-02-15 2015-10-05 Tolmar Therapeutics Inc Lavsprængning poly-(laktid/glykolid) og fremgangsmåder til at fremstille polymerer
KR101612901B1 (ko) 2007-03-02 2016-04-15 테이카 세이야쿠 가부시키가이샤 경피흡수 의약조성물, 의약조성물 저장유닛 및 이것을 이용하는 경피흡수제제
JP2010523564A (ja) 2007-04-03 2010-07-15 トリメリス，インコーポレーテッド 抗ウイルス性ペプチド治療薬の送達のための新規製剤
CA2686137C (en) 2007-05-18 2021-01-12 Durect Corporation Improved depot formulations
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
DK2197429T3 (da) 2007-09-03 2016-05-30 Nanotherapeutics Inc Partikelsammensætninger til levering af svært opløselige lægemidler
US9254268B2 (en) 2007-09-25 2016-02-09 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
WO2009088414A2 (en) 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
FR2926996B1 (fr) 2008-01-31 2013-06-21 Ethypharm Sa Composition pharmaceutique a proprietes gelifiantes contenant un derive de tyrosine
AU2009212373B2 (en) 2008-02-08 2013-10-03 Foresee Pharmaceuticals Co., Ltd. Non-polymeric compositions for controlled drug delivery
AU2009212367B2 (en) 2008-02-08 2013-08-01 Foresee Pharmaceuticals Co., Ltd. Composition for sustained release delivery of proteins or peptides
JP5286850B2 (ja) 2008-03-14 2013-09-11 大日本印刷株式会社 液体用紙容器用包装材料およびその包装材料から製造される液体用紙容器
US20090246265A1 (en) 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
CA2726763A1 (en) 2008-06-03 2009-12-10 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
HRP20150350T1 (hr) 2008-06-03 2015-05-08 Tolmar Therapeutics, Inc. Tekuä†i pripravak koji sadrži biokompatibilne pripravke oligomer-polimer
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
EP2421503A1 (en) 2009-04-23 2012-02-29 Londonpharma Ltd. Sublingual pharmaceutical composition comprising a neutral oil
RU2554740C2 (ru) 2009-05-01 2015-06-27 Апталис Фарматек, Инк. Композиции перорально распадающихся таблеток, содержащие комбинации высоко- и низкодозовых лекарственных средств
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
EA024533B1 (ru) 2009-11-18 2016-09-30 Нектар Терапьютикс Формы солей кислот конъюгатов полимер-лекарственное средство
WO2011088140A1 (en) 2010-01-12 2011-07-21 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
JP5977225B2 (ja) 2010-03-15 2016-08-24 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． 成長ホルモン分泌促進物質受容体リガンドの医薬組成物
US20110230816A1 (en) 2010-03-18 2011-09-22 Tyco Healthcare Group Lp Gels for Transdermal Delivery
EP2529756B1 (en) 2011-05-31 2021-05-19 Laboratorios Farmaceuticos Rovi, S.A. Risperidone and/or Paliperidone implant formulation
ES2589106T3 (es) 2010-05-31 2016-11-10 Laboratorios Farmaceuticos Rovi, S.A. Composición inyectable antipsicótica de liberación controlada
HRP20211853T1 (hr) 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Sastavi in situ injekcijskih biorazgradivih implantata
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
NZ609200A (en) 2010-09-21 2015-01-30 Purdue Pharma Lp Buprenorphine analogs
CN103200944B (zh) 2010-11-17 2016-05-04 赫克萨尔股份公司 包含丁丙诺啡的经皮治疗系统
CN103429266A (zh) 2010-11-26 2013-12-04 约翰内斯堡金山大学 药物递送装置
AU2012327247B2 (en) 2011-12-12 2015-12-24 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US20140134261A1 (en) 2012-08-21 2014-05-15 Trinity Laboratories, Inc. Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores
RU2513514C1 (ru) 2012-11-23 2014-04-20 Общество с ограниченной ответственностью "НПК "Трифарма" Фармацевтическая композиция, содержащая налбуфина гидрохлорид, ее применение для лечения болевого синдрома средней и высокой интенсивности и способ получения фармацевтической композиции
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
BR112015022023B1 (pt) 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US20160303038A1 (en) 2013-11-21 2016-10-20 Pawar Harshal Ashok Oral films
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices

Also Published As

Publication number Publication date
US8852638B2 (en) 2014-10-07
US11110093B2 (en) 2021-09-07
AU2006299657A1 (en) 2007-04-12
ES2385384T3 (es) 2012-07-24
EP1940351A2 (en) 2008-07-09
IL190499A0 (en) 2008-11-03
ES2422681T3 (es) 2013-09-13
CA2624088A1 (en) 2007-04-12
US10406160B2 (en) 2019-09-10
TW200803920A (en) 2008-01-16
JP5934685B2 (ja) 2016-06-15
CN101365423B (zh) 2012-11-21
IL190499A (en) 2016-04-21
EP2361609A1 (en) 2011-08-31
US20140086990A1 (en) 2014-03-27
US20180325905A1 (en) 2018-11-15
US10058554B2 (en) 2018-08-28
WO2007041410A2 (en) 2007-04-12
US20150231258A1 (en) 2015-08-20
JP2009510116A (ja) 2009-03-12
CN101365423A (zh) 2009-02-11
EP1940351B1 (en) 2012-04-04
US20200046704A1 (en) 2020-02-13
US9597402B2 (en) 2017-03-21
JP6216364B2 (ja) 2017-10-18
DK1940351T3 (da) 2012-07-02
AU2006299657B2 (en) 2013-03-21
JP2014012712A (ja) 2014-01-23
PL2361609T3 (pl) 2013-10-31
EP2361609B1 (en) 2013-07-17
JP2016128411A (ja) 2016-07-14
US20170239252A1 (en) 2017-08-24
CA2624088C (en) 2016-03-08
US9044450B2 (en) 2015-06-02
AR056554A1 (es) 2007-10-10
US20070077304A1 (en) 2007-04-05
WO2007041410A3 (en) 2007-07-12
ATE551989T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
DK2361609T3 (da) Formulering af småmolekylære lægemidler med forsinket frigivelse
CY2014011I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
BRPI0511900A (pt) composições farmacêuticas
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
DK2046264T3 (da) Fremgangsmåder til fremstillingen af sammensætninger med film
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
NL300998I2 (nl) Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
DK1984009T3 (da) Farmaceutiske sammensætninger med forbedret stabilitet
NO20075628L (no) Farmasøytiske formuleringer
DK1830850T3 (da) Quinolin-derivater til behandling af latent tuberkulose
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
PT1850664E (pt) Formulação de cápsulas
NO20091266L (no) Fremgangsmåter for administrering av langvarige hypoglykemiske midler
DK2146991T3 (da) Triazolopyridin-carboxamid-derivater, fremstilling af samme samt terapeutisk anvendelse deraf
DK1954241T3 (da) Zonisamid-formulering med vedvarende frigivelse
CR9144A (es) Formulaciones de benzoxazoles sustituidos
NO20043305D0 (no) Preparation of lodixanol
EP1721604A4 (en) STABLE CAPSULE PREPARATION